Whole body vibration compared to conventional physiotherapy in patients with gonarthrosis: a protocol for a randomized, controlled study

Gregor Stein, Peter Knoell, Christoph Faymonville, Thomas Kaulhausen, Jan Siewe, Christina Otto, Peer Eysel, Kourosh Zarghooni, Gregor Stein, Peter Knoell, Christoph Faymonville, Thomas Kaulhausen, Jan Siewe, Christina Otto, Peer Eysel, Kourosh Zarghooni

Abstract

Background: Osteoarthritis (OA) is the most common degenerative arthropathy. Load-bearing joints such as knee and hip are more often affected than spine or hands. The prevalence of gonarthrosis is generally higher than that of coxarthrosis.Because no cure for OA exists, the main emphasis of therapy is analgesic treatment through either mobility or medication. Non-pharmacologic treatment is the first step, followed by the addition of analgesic medication, and ultimately by surgery.The goal of non-pharmacologic and non-invasive therapy is to improve neuromuscular function, which in turn both prevents formation of and delays progression of OA. A modification of conventional physiotherapy, whole body vibration has been successfully employed for several years. Since its introduction, this therapy is in wide use at our facility not only for gonarthrosis, but also coxarthrosis and other diseases leading to muscular imbalance.

Methods/design: This study is a randomized, therapy-controlled trial in a primary care setting at a university hospital. Patients presenting to our outpatient clinic with initial symptoms of gonarthrosis will be assessed against inclusion and exclusion criteria. After patient consent, 6 weeks of treatment will ensue. During the six weeks of treatment, patients will receive one of two treatments, conventional physiotherapy or whole-body-vibration exercises of one hour three times a week. Follow-up examinations will be performed immediately after treatment and after another 6 and 20 weeks, for a total study duration of 6 months. 20 patients will be included in each therapy group.Outcome measurements will include objective analysis of motion and ambulation as well as examinations of balance and isokinetic force. The Western Ontario and McMaster Universities Arthritis Index and SF-12 scores, the patients' overall status, and clinical examinations of the affected joint will be carried out.

Discussion: As new physiotherapy techniques develop for the treatment of OA, it is important to investigate the effectiveness of competing strategies. With this study, not only patient-based scores, but also objective assessments will be used to quantify patient-derived benefits of therapy.

Trial registration: Deutsches Register Klinischer Studien (DRKS) DRKS00000415Clinicaltrials.gov NCT01037972EudraCT 2009-017617-29.

References

    1. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, Zummer M. The role of viscosupplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis Cartilage. 1995;3(4):213–25. doi: 10.1016/S1063-4584(05)80013-5.
    1. Pelletier JP, Martel-Pelletier J. The pathophysiology of osteoarthritis and the implication of the use of hyaluronan and hylan as therapeutic agents in viscosupplementation. J Rheumatol Suppl. 1993;39:19–24.
    1. Wobig M, Bach G, Beks P, Dickhut A, Runzheimer J, Schwieger G, Vetter G, Balazs E. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther. 1999;21(9):1549–62. doi: 10.1016/S0149-2918(00)80010-7.
    1. Cunningham LS, Kelsey JL. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health. 1984;74(6):574–9. doi: 10.2105/AJPH.74.6.574.
    1. Mikkelsen WM, Dodge HJ, Duff IF, Kato H. Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. J Chronic Dis. 1967;20(6):351–69. doi: 10.1016/0021-9681(67)90009-4.
    1. van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis. 1989;48(4):271–80. doi: 10.1136/ard.48.4.271.
    1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343–55. doi: 10.1002/1529-0131(199808)41:8<1343::AID-ART3>;2-9.
    1. Oliveria SA, Felson DT, Reed JI, Cirillo PA, Walker AM. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 1995;38(8):1134–41. doi: 10.1002/art.1780380817.
    1. Duchow J, Kohn D. Treatment of knee joint arthritis in the middle-aged patient. Orthopade. 2003;32(10):920–29. doi: 10.1007/s00132-003-0566-3. quiz 30.
    1. Pullig O, Pfander D, Swoboda B. Molecular principles of induction and progression of arthrosis. Orthopade. 2001;30(11):825–33. doi: 10.1007/s001320170018.
    1. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039–49. doi: 10.1002/art.1780290816.
    1. ACR. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum. 2000;43(9):1905–15. doi: 10.1002/1529-0131(200009)43:9<1905::AID-ANR1>;2-P. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.
    1. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee.American College of Rheumatology. Arthritis Rheum. 1995;38(11):1541–6. doi: 10.1002/art.1780381104.
    1. Steinmeyer J. Drug therapy of arthrosis. Orthopade. 2001;30(11):856–65. doi: 10.1007/s001320170022.
    1. Sharma L. The role of proprioceptive deficits, ligamentous laxity, and malalignment in development and progression of knee osteoarthritis. J Rheumatol Suppl. 2004;70:87–92.
    1. Da Silva-Grigoletto ME, Vaamonde DM, Castillo E, Poblador MS, Garcia-Manso JM, Lancho JL. Acute and cumulative effects of different times of recovery from whole body vibration exposure on muscle performance. J Strength Cond Res. 2009;23(7):2073–82.
    1. Rees SS, Murphy AJ, Watsford ML. Effects of whole-body vibration exercise on lower-extremity muscle strength and power in an older population: a randomized clinical trial. Phys Ther. 2008;88(4):462–70.
    1. Rauch F. Vibration therapy. Dev Med Child Neurol. 2009;51(Suppl 4):166–8. doi: 10.1111/j.1469-8749.2009.03418.x.
    1. Trans T, Aaboe J, Henriksen M, Christensen R, Bliddal H, Lund H. Effect of whole body vibration exercise on muscle strength and proprioception in females with knee osteoarthritis. Knee. 2009;16(4):256–61. doi: 10.1016/j.knee.2008.11.014.
    1. Bellamy N. WOMAC: a 20-year experiential review of a patient-centered self-reported health status questionnaire. J Rheumatol. 2002;29(12):2473–6.
    1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–40.
    1. EMEA. Committee for proprietary medicinal products (CPMP). Points to consider on clinical ionvestigations of medicinal products used in the treatment of Osteoarthritis (CPMP/EWP/784/97) Electronic Citation. 1998.
    1. Bellamy N. The WOMAC Knee and Hip Osteoarthritis Indices: development, validation, globalization and influence on the development of the AUSCAN Hand Osteoarthritis Indices. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S148–53.
    1. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2005. p. CD005321.
    1. Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004;12(5):389–99. doi: 10.1016/j.joca.2004.02.001.
    1. Radoschewski M, Bellach BM. The SF-36 in the Federal Health Survey--possibilities and requirements for application at the population level. Gesundheitswesen. 1999. 61 Spec No:S191-9.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner